NCT02878772View on ClinicalTrials.gov

Vinpocetine Inhibits NF-κB-dependent Inflammation in Acute Ischemic Stroke Patients

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
StrokeImmunoregulationInflammationVinpocetine
Interventions
DRUG

vinpocetine

30 mg of the drug by intravenous infusion once daily, for fourteen consecutive days, beginning within one hour after the baseline MRI and no later than 48 hours after the onset of symptoms.

DRUG

Aspirin

100mg, once daily, oral medication

All Listed Sponsors
lead

Tianjin Medical University General Hospital

OTHER

NCT02878772 - Vinpocetine Inhibits NF-κB-dependent Inflammation in Acute Ischemic Stroke Patients | Biotech Hunter | Biotech Hunter